Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunology

Graph Therapeutics, decoding immune dysfunction at scale, led by Gregory Vladimer, PhD, Robert Sehlke, PhD, Prof. Berend Snijder, PhD, Bojan Vilagos, PhD, and Christophe Boudesco, PhD, has announced that Daphni, the Paris-based venture capital firm, has joined Graph’s investor syndicate to accelerate its internal pipeline. Daphni invests alongside continued participation from existing investors SquareOne, Merantix Capital, and NAVEC Investment Management, with additional non-dilutive grant funding provided by the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice (AWS). This new investment of $5M brings Graph’s total funding to date to over $10 million, including non-dilutive.

Advancing the Platform.

Graph is expanding its internal drug discovery pipeline across multiple inflammatory and immune-mediated diseases, supported by a platform validated in clinically relevant biological models. The company's platform also creates opportunities for strategic partnerships and out-licensing, extending its impact beyond its proprietary pipeline. The new funding will support continued platform development and the advancement of differentiated therapies.

CEO Commentary.

Graph Therapeutics Co-founder and CEO Gregory Vladimer, PhD, said the company's platform has reached a key stage where biological insights are directly informing its drug discovery programs. The new investment will support the expansion of precision medicine programs in inflammatory and immune-mediated diseases while accelerating the translation of immune system insights into novel therapies.

Investor Commentary.

Daphni Partner Sofia Dahoune said Graph Therapeutics represents a new generation of techbio companies that combine advanced technology with rigorous drug discovery. The firm believes the company's integrated approach is well-suited to addressing the complexity of immune-mediated diseases and supporting the advancement of its therapeutics pipeline.

Graph Therapeutics combines live patient cell models with machine learning to uncover disease mechanisms, identify drug targets, and discover biomarkers for immune-mediated diseases. Building on the founding team's experience in AI-driven precision oncology, the company applies a lab-in-the-loop approach to accelerate drug discovery. In addition to venture funding, Graph has received non-dilutive grants from Austria's leading life sciences innovation programs, providing further validation of its scientific platform.